Showing results (121-130 of 332) with videos related to
Sort By:
Pageof 34
Neurology(R) Neuroimmunology & Neuroinflammation|February 26, 2019
Cranial nerve involvement in patients with MOG antibody-associated diseaseAlvaro Cobo-Calvo, Xavier Ayrignac, Philippe Kerschen, et al.Journal of Neurology|February 8, 2019
Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in FranceChristine Lebrun-Frenay, Antoine Moulignier, Charles Pierrot-Deseilligny, et al.Neurology and Therapy|December 19, 2022
Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple SclerosisCaroline Ruetsch-Chelli, Darin T Okuda, Fanny Rocher, et al.Journal of Neuroimmunology|September 10, 2016
Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravisChristine Lebrun, Véronique Bourg, Saskia Bresch, et al.Developmental Medicine and Child Neurology|June 23, 2020
Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromesKumaran Deiva, Alvaro Cobo-Calvo, Hélène Maurey, et al.Multiple Sclerosis and Related Disorders|August 25, 2022
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE studyEric Manchon, David Laplaud, Sandra Vukusic, et al.The Lancet Regional Health. Europe|November 25, 2022
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort studySarah Wilson, Floriane Calocer, Fabien Rollot, et al.JAMA Network Open|June 23, 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple SclerosisEdouard Januel, David Hajage, Pierre Labauge, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2020
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple SclerosisSophie Mathais, Xavier Moisset, Bruno Pereira, et al.Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.Pageof 34